Skip to main content
. 2021 Jan 20;11:603947. doi: 10.3389/fneur.2020.603947

Figure 4.

Figure 4

Forest plot of 6-month PFS in glioblastoma between lomustine plus bevacizumab and control groups. Six-month PFS, the percentage of patients who could progression-free survival for 6 months; Lom, lomustine; Bev, bevacizumab.